Katherine Vega Stultz

Katherine Vega Stultz has worked in the biopharmaceutical industry since 1995. Katherine Vega began their career as a Product Engineer, Project Manager, and Territory Manager at ConvaTec. In 2000, they moved to Eli Lilly and Company as a Marketing Associate, where they worked on pipeline products and new indications across oncology, cardiovascular, and neuroscience therapeutic areas. In 2005, they joined Celgene as a District Sales Manager, Mid-Atlantic District. Katherine Vega then moved up the ranks to Executive Director, Global Project Leader & US Brand Leader, Director, Patient Support & Reimbursement Services, and CVP Global Project & Portfolio Management Hematology/Oncology. In 2020, they became the Chief Operating Officer for Graphite Bio, a clinical-stage, next-generation gene editing company. Currently, they are the President and CEO of Ocelot Bio, a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics.

Katherine Vega Stultz holds a Bachelor of Science (B.S.) in Mechanical Engineering with Concentration in Biomedical Applications from Cornell University. Katherine Vega is also certified as a Project Management Professional (PMP) by the Project Management Institute and holds a Regulatory Affairs Certificate from the Regulatory Affairs Professionals Society (RAPS).